NEUWERK advises University Hospital Cologne on license and cooperation agreement with BioNTech
28 September 2022
On September 28, 2022, University Hospital Cologne announced that it had concluded a licensing and cooperation agreement with BioNTech to research new approaches for the treatment of HIV. NEUWERK advised the hospital in this transaction.
The partnership brings together the hospital’s many years of experience in identifying and testing innovative approaches to treat the human immunodeficiency virus (HIV) and BioNTech’s expertise in immunotherapy and its proprietary mRNA vaccine platform. The aim of the research partnership is to investigate new potential strategies to treat HIV and to test them in further studies.
The NEUWERK team consisted of Börge Seeger, MLE (Leuven), JSM (Stanford) and Daniel Schuppmann, LL.M.